{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T03:16:14Z","timestamp":1782011774853,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.lungcan.2024.107843","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T15:57:20Z","timestamp":1717171040000},"page":"107843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB\/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06\u20132018 study)"],"prefix":"10.1016","volume":"193","author":[{"given":"Lyria","family":"Amari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-0666","authenticated-orcid":false,"given":"Emmanuelle","family":"Dantony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Rousseau-Bussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ricordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bigay-Game","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Arpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Justeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Huchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3884-6816","authenticated-orcid":false,"given":"Pierre","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Vergnenegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7876","authenticated-orcid":false,"given":"Acya","family":"Bizeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-2019","authenticated-orcid":false,"given":"Fabien","family":"Subtil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-9503","authenticated-orcid":false,"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bylicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lungcan.2024.107843_b0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107843_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China","volume":"16","author":"Cheng","year":"2021","journal-title":"A Randomized Study. Targ Oncol."},{"key":"10.1016\/j.lungcan.2024.107843_b0015","doi-asserted-by":"crossref","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):339-357. doi: 10.1016\/j.annonc.2022.12.009.","DOI":"10.1016\/j.annonc.2022.12.009"},{"issue":"8","key":"10.1016\/j.lungcan.2024.107843_b0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"issue":"10030","key":"10.1016\/j.lungcan.2024.107843_b0025","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"10027","key":"10.1016\/j.lungcan.2024.107843_b0030","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.lungcan.2024.107843_b0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107843_b0040","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018726","article-title":"Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma","volume":"99","author":"Bylicki","year":"2020","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.lungcan.2024.107843_b0045","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107843_b0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107843_b0055","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107843_b0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.lungcan.2024.107843_b0065","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2147\/OTT.S100164","article-title":"Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment","volume":"9","author":"Yang","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107843_b0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jtho.2021.11.012","article-title":"Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer","volume":"17","author":"Muthusamy","year":"2022","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.lungcan.2024.107843_b0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lungcan.2021.07.004","article-title":"Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure","volume":"159","author":"Am","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107843_b0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.014","volume":"183","author":"Bylicki","year":"2023","journal-title":"Eur J Cancer."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107843_b0085","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107843_b0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0885-3924(99)00150-5","article-title":"Symptoms in adults with lung cancer. A systematic research review","volume":"19","author":"Cooley","year":"2000","journal-title":"J Pain Symptom Manage."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107843_b0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107843_b0100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur J Cancer."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107843_b0105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","article-title":"Quality of Life Committee of the NCIC CTG. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group","volume":"41","author":"Osoba","year":"2005","journal-title":"Eur J Cancer."},{"issue":"17_suppl","key":"10.1016\/j.lungcan.2024.107843_b0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9000","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study","volume":"41","author":"Yang","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2024.107843_b0115","first-page":"41","article-title":"CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC","volume":"14","author":"Lee","year":"2023","journal-title":"Lung Cancer (auckl)."},{"key":"10.1016\/j.lungcan.2024.107843_b0120","doi-asserted-by":"crossref","unstructured":"Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024:JCO2301017. doi: 10.1200\/JCO.23.01017.","DOI":"10.1200\/JCO.23.01017"},{"issue":"5","key":"10.1016\/j.lungcan.2024.107843_b0125","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00520-014-2148-9","article-title":"Effect of chemotherapy on quality of life in patients with non-small cell lung cancer","volume":"22","author":"Mannion","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2024.107843_b0130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s11136-007-9210-8","article-title":"Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting","volume":"16","author":"Nicklasson","year":"2007","journal-title":"Qual Life Res."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107843_b0135","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107843_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2024.107843_b0145","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.2017.77.2293","article-title":"Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107843_b0150","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jamaoncol.2016.3328","article-title":"Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials","volume":"3","author":"Atkinson","year":"2017","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107843_b0155","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jnci\/djy181","article-title":"Blinding and Patient-Reported Outcome Completion Rates in US Food and Drug Administration Cancer Trial Submissions, 2007\u20132017","volume":"111","author":"Roydhouse","year":"2019","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107843_b0160","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11764-020-00853-3","article-title":"The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life","volume":"14","author":"Park","year":"2020","journal-title":"J Cancer Surviv."},{"issue":"26","key":"10.1016\/j.lungcan.2024.107843_b0165","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107843_b0170","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/annonc\/mdw258","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T05:35:36Z","timestamp":1727242536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224003775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"alternative-id":["S0169500224003775"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107843","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB\/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06\u20132018 study)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107843"}}